Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022003061 - MUCINS AND ISOFORMS THEREOF IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION

Publication Number WO/2022/003061
Publication Date 06.01.2022
International Application No. PCT/EP2021/068083
International Filing Date 30.06.2021
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • UNIVERSITEIT ANTWERPEN [BE]/[BE]
Inventors
  • SMET, Annemieke
  • DE WINTER, Benedicte
  • BREUGELMANS, Tom
Agents
  • ARNOLD & SIEDSMA BV
Priority Data
21152072.118.01.2021EP
21157750.718.02.2021EP
PCT/EP2020/06834030.06.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) MUCINS AND ISOFORMS THEREOF IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION
(FR) MUCINES ET LEURS ISOFORMES UTILISÉES DANS DES MALADIES CARACTÉRISÉES PAR UN DYSFONCTIONNEMENT DE BARRIÈRE
Abstract
(EN) The present invention relates to the field of mucins and isoforms thereof, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... more in particular coronaviral infections In a specific embodiment, said mucins and/or isoforms thereof are selected from the list comprising: MUC16, MUC21, MUC20, MUC2, MUC4, MUC5AC, MUC5B, MUC13, and MUC1 and isoforms thereof
(FR) La présente invention concerne le domaine des mucines et des isoformes de celles-ci, en particulier pour une utilisation dans le diagnostic, la surveillance, la prévention et/ou le traitement d'une maladie caractérisée par un dysfonctionnement de barrière, tel que, mais sans y être limité, un trouble gastro-intestinal (par ex., une maladie intestinale inflammatoire (IBD), le syndrome du côlon irritable (IBS), le cancer, les infections gastro-intestinales, l'obésité, la stéatose hépatique non alcoolique (NAFLD), les troubles neurodégénératifs, les infections respiratoires, ..., plus particulièrement, des infections à coronavirus. Dans un mode de réalisation spécifique, lesdites mucines et/ou lesdits isoformes de celles-ci sont sélectionnés dans la liste comprenant : MUC16, MUC21, MUC20, MUC2, MUC4, MUC5AC, MUC5B, MUC13, et MUC1 et des isoformes de celles-ci
Latest bibliographic data on file with the International Bureau